Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Study Details
Study Description
Brief Summary
The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Early Phase 1 |
Detailed Description
Chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia (WM) are known risk factors for zoster reactivation, commonly called shingles. Although a recently FDA-approved recombinant, adjuvanted herpes zoster vaccine (Shingrix) is currently being offered to these populations, no study has specifically evaluated them.
The purpose of the study is to complete a single-arm trial evaluating if patients with CLL or WM, while on treatment with first-line BTK inhibitors, can achieve immunologic response to Shingrix. If effective, this will result in a new, well-tolerated shingles prevention strategy for these patients.
The primary objective is to assess the capability to mount a humoral immune response to Shingrix in patients with CLL or WM under first-line BTK inhibitors.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Shingrix shingles vaccine treatment On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose. |
Drug: Shingrix vaccine
On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- A four-fold increase from baseline in serum immunoglobulin geometric mean titer to the gE viral antigen determined by enzyme linked immunosorbent assay (ELISA) at 4 weeks after vaccination. [4 weeks following vaccination]
Vaccine response, as determined by blood antibody levels to the varicella virus glycoprotein E subunit (anti-gE); Baseline is defined as pre-vaccination anti-gE titer in seropositive subjects, and the lower limit of detection in seronegative subjects
Secondary Outcome Measures
- Proportion of patients with humoral immunity at 4 weeks after vaccination [4 weeks following vaccination]
Blood draws performed to measure persistence of measurable anti-gE and cellular-mediated immunity; cellular-mediated response will be determined by measuring PMBC activation (by ELISPOT or flow cytometry) following stimulation with varicella glycoprotein E peptide. PBMC activation at 4 weeks and 1 year post dose will be compared to pre-vaccination activation levels.
Other Outcome Measures
- A four-fold increase from baseline in serum immunoglobulin geometric mean titer to the gE viral antigen determined by enzyme linked immunosorbent assay (ELISA) at 2 years after vaccination. [2 years following vaccination]
Vaccine response, as determined by blood antibody levels to the varicella virus glycoprotein E subunit (anti-gE); Baseline is defined as pre-vaccination anti-gE titer in seropositive subjects, and the lower limit of detection in seronegative subjects
- Proportion of patients with humoral immunity at 2 years after vaccination [2 years following vaccination]
Blood draws performed to measure persistence of measurable anti-gE and cellular-mediated immunity; cellular-mediated response will be determined by measuring PMBC activation (by ELISPOT or flow cytometry) following stimulation with varicella glycoprotein E peptide. PBMC activation at 4 weeks and 2 years post dose will be compared to pre-vaccination activation levels.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
They are at least 50 years of age;
-
Have been diagnosed with chronic lymphocytic leukemia (CLL) OR Waldenström's macroglobulinemia (WM)
-
Have been on first-line BTK inhibitor (ie ibrutinib or acalabrutinib) for at least 3 months,
-
Prior treatment with single agent rituximab is permitted if last dose was administered over one year ago;
-
Have at least a one-year life expectancy;
-
Have a history of varicella (chicken-pox) OR lived in the US or any endemic country for > 30 years.
-
Prior radiation therapy is allowed
Exclusion Criteria:
-
They have a known hypersensitivity to a vaccine component;
-
Had herpes zoster reactivation within the past year;
-
Had received or were scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post-second dose;
-
Had received or were scheduled to receive an inactivated vaccine in the period ranging from 7 days prior to Dose 1 through 7 days post- second dose;
-
Are unable to give informed consent;
-
Have absolute lymphocyte counts greater than 20,000 X 109/L;
-
Are receiving treatment for CLL or WM with an additional agent other than a BTK inhibitor;
-
Had rituximab treatment within a year prior to study start;
-
Had prior chemotherapy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Rochester | Rochester | New York | United States | 14623 |
Sponsors and Collaborators
- University of Rochester
Investigators
- Principal Investigator: Jonathan Friedberg, MD, University of Rochester
Study Documents (Full-Text)
More Information
Publications
None provided.- 00003112